Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Compliance Quarterly Türkiye
Anti-bribery and corruption
Authors:
Global | Publication | August 2024
Global
Failure to prevent fraud: What to do now? Part 2: Policies and procedures
Our regulation and investigations team has published the second article in their series on how companies will need to implement “reasonable procedures” to prevent fraud.
Read the full Inside Disputes blog, "Failure to prevent fraud: What to do now? Part 2: Policies and procedures."
Türkiye
Sanctions are imposed on Israel by Türkiye
In April 2024, the Republic of Türkiye has imposed sanctions on Israel, banning the export of 54 product groups (identified for potential military use) in response to Israel’s failure to comply with the binding decisions of the United Nations Security Council and the International Court of Justice. A month later, Türkiye announced that they extended the trade ban on Israel to an exportation and importation restriction covering all products.
While specific penalties for non-compliance have not been specified, it has been reported that in practice no products coming from Israel or destined for Israel are processed at Turkish customs. The penalties for and requirements arising from the non-compliance are expected to be announced shortly.
Recent publications
Publication
Country risk in unprecedented times: A precedent for cross-border loan documentation?
While country risk cannot be avoided in cross-border transactions entirely, it can be effectively mitigated through careful transaction structuring and tailored contractual protections.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .